Core Viewpoint - A class action securities lawsuit has been filed against TransMedics Group, Inc. alleging securities fraud that affected investors between February 28, 2023, and January 10, 2025 [1][2]. Group 1: Allegations - The lawsuit claims that TransMedics engaged in kickbacks, fraudulent overbilling, and coercive tactics to generate business and revenue [2]. - It is alleged that the company engaged in unsafe practices, concealed safety issues, and lacked proper safety oversight [2]. - The aforementioned actions subjected TransMedics to increased scrutiny and regulatory risk, leading to materially false and misleading statements about its business and operations [2]. Group 2: Legal Process - Investors who suffered losses during the specified timeframe have until April 15, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

RADNOR, Pa., Feb. 24, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against TransMedics Group, Inc. ("TransMedics") (NASDAQ: TMDX) on behalf of those who purchased or otherwise acquired TransMedics securities between February 28, 2023, and January 10, 2025, inclusive (the "Class Period"). The lead plaintiff deadline is April 15, 2025.CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP:If you suffered Tran ...

Core Viewpoint - A lawsuit has been filed against TransMedics Group, Inc. and certain senior executives for potential violations of federal securities laws, alleging misrepresentation and fraudulent practices [1][2][4]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of Massachusetts, captioned Jewik v. TransMedics Group, Inc. et al, No. 25-cv-10385 [2]. - Investors have until April 15, 2025, to request to be appointed to lead the case [2]. Group 2: Company Background - TransMedics is a commercial-stage medical technology company known for its "Organ Care System" (OCS), which maintains donor organs' viability before transplant [3]. Group 3: Allegations - The complaint alleges that TransMedics misrepresented its business practices, claiming they were driven by kickbacks, fraudulent overbilling, and coercive tactics [4]. - It is further alleged that the company engaged in unsafe practices involving OCS, concealed safety issues, and lacked proper safety oversight [4]. Group 4: Stock Performance - Following allegations of misconduct from U.S. Representative Paul Gosar, TransMedics' stock price fell approximately 4%, from $86.99 on February 21, 2024, to $83.14 on February 23, 2024 [5]. - After a report from Scorpion Capital on January 10, 2025, which accused TransMedics of anti-competitive schemes and billing fraud, the stock price declined an additional 5%, from $72.55 on January 8, 2025, to $68.81 on January 10, 2025 [6].

Core Viewpoint - The TransMedics Group, Inc. is facing a class action lawsuit alleging violations of the Securities Exchange Act of 1934, with claims of misconduct including fraudulent practices and safety issues [1][3][4]. Group 1: Class Action Lawsuit Details - The class action lawsuit is titled Jewik v. TransMedics Group, Inc., and covers purchasers of TransMedics securities from February 28, 2023, to January 10, 2025 [1]. - Investors have until April 15, 2025, to seek appointment as lead plaintiff in the lawsuit [1]. - The lawsuit alleges that TransMedics used kickbacks, fraudulent overbilling, and coercive tactics to generate business [3]. Group 2: Allegations Against TransMedics - Allegations include unsafe practices and a lack of safety oversight, which heightened regulatory scrutiny risks [3]. - A letter from U.S. Representative Paul Gosar on February 21, 2024, accused TransMedics of misconduct, leading to a decline in stock price [4]. - A report from Scorpion Capital on January 10, 2025, accused TransMedics of overbilling and providing rejected organs to patients, further impacting stock price negatively [5]. Group 3: Legal Process and Representation - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased TransMedics securities during the class period to seek lead plaintiff status [6]. - The lead plaintiff represents the interests of all class members and can choose a law firm for litigation [6]. Group 4: About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud cases, having recovered $6.6 billion for investors in class action cases [7]. - The firm has been ranked 1 in securing monetary relief for investors for six out of the last ten years [7].

NEW YORK, Feb. 24, 2025 /PRNewswire/ --  The Gross Law Firm issues the following notice to shareholders of TransMedics Group, Inc. (NASDAQ: TMDX).Shareholders who purchased shares of TMDX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/transmedics-group-inc-loss-submission-form-2/?id=131216&from=4CLASS PERIOD: Febr ...

Group 1 - The importance of reliable and advancing medical equipment is increasing, particularly in the field of organ transplantation due to the growing issue of end-stage organ failure worldwide [1]

Core Viewpoint - A class action lawsuit has been filed against TransMedics Group, Inc. for violations of federal securities laws, impacting investors who purchased shares during the specified Class Period [1][2]. Group 1: Lawsuit Details - The lawsuit alleges that TransMedics and its officers made false or misleading statements and failed to disclose critical information regarding the company's business practices [2]. - Specific allegations include the use of kickbacks, fraudulent overbilling, and coercive tactics to generate revenue, as well as unsafe practices and lack of safety oversight [2]. Group 2: Impact on Investors - Following the revelation of these issues, TransMedics' stock experienced a significant decline, resulting in financial losses for investors [3]. - Investors who suffered losses exceeding $100,000 are encouraged to participate in the lawsuit, with a deadline to act by April 15, 2025 [3]. Group 3: About the Law Firm - Lowey Dannenberg P.C. specializes in representing investors who have suffered financial losses due to corporate fraud and has a history of recovering billions for clients [4].

Core Viewpoint - A class-action lawsuit has been filed against TransMedics Group, Inc. alleging fraudulent practices and safety issues, impacting investors who acquired securities between February 28, 2023, and January 10, 2025 [1][2]. Group 1: Allegations and Claims - The lawsuit claims that TransMedics made false and misleading statements, failed to disclose crucial information, and engaged in kickbacks, fraudulent overbilling, and coercive tactics to enhance business and revenue [2][5]. - It is alleged that the company concealed safety problems and lacked adequate safety oversight, which exposed it to increased regulatory risk [2][5]. Group 2: Events Impacting Stock Price - On February 21, 2024, Representative Paul Gosar accused TransMedics of misappropriating corporate resources, leading to a stock price drop following media coverage [3]. - A report released by activist short seller Scorpion Capital on January 10, 2025, accused TransMedics of overbilling hospitals and coercing customers, further depressing the company's stock price [4]. Group 3: Investigation and Legal Proceedings - Hagens Berman is investigating the claims against TransMedics and is urging investors who suffered losses to come forward [2][5]. - The lead plaintiff deadline for the class-action lawsuit is set for April 15, 2025 [2].

Core Viewpoint - A class action securities lawsuit has been filed against TransMedics Group, Inc. for alleged securities fraud affecting investors between February 28, 2023, and January 10, 2025 [1][2]. Group 1: Allegations Against TransMedics - The lawsuit claims that TransMedics engaged in kickbacks, fraudulent overbilling, and coercive tactics to generate business and revenue [2]. - It is alleged that the company engaged in unsafe practices, concealed safety issues, and lacked proper safety oversight [2]. - The aforementioned actions reportedly increased the company's risk of scrutiny and regulatory challenges, leading to materially false and misleading statements about its business and operations [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until April 15, 2025, to request to be appointed as lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, and participation does not require serving as a lead plaintiff [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

Core Viewpoint - A securities class action lawsuit has been filed against TransMedics Group, Inc. for alleged misconduct during the Class Period from February 28, 2023, to January 10, 2025 [1] Allegations Against TransMedics - The complaint alleges that TransMedics engaged in kickbacks, fraudulent overbilling, and coercive tactics to generate business and revenue [3] - It is claimed that the company engaged in unsafe practices, concealed safety issues, and lacked proper safety oversight [3] - These actions purportedly exposed TransMedics to increased scrutiny and regulatory risks [3] Lead Plaintiff Process - Investors in TransMedics have until April 15, 2025, to seek appointment as a lead plaintiff representative for the class [4] - A lead plaintiff acts on behalf of all class members and is typically the investor or group of investors with the largest financial interest [4] - The decision to serve as a lead plaintiff does not affect the ability to share in any recovery [4]